Health Technology Peptidream, Inc. Business Summary
PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. It produces macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS). The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.
Financial Highlights
Dec 2021
JPY USD Revenue 9,365.96M 85.24M Gross Profit 6,937.89M 63.14M Operating income 4,418.14M 40.21M Income before tax 4,823.65M 43.90M Net income 3,606.40M 32.82M EBITDA 5,051.15M 45.97M Diluted EPS 27.77 0.25 Dividends Per Share 0 0 Total Assets 26,619.16M 231.15M Total liabilities 1,620.57M 14.07M Total equity 24,998.59M 217.08M Operating cash flow 6,654.70M 60.56M Currency in JPY Currency in USD
Historical Data Jun 2017 Jun 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
4,895.74M
6,426.89M
2,074.67M
11,677.25M
9,365.96M
Gross Profit
3,530.02M
4,648.26M
661.06M
9,459.96M
6,937.89M
Operating income
2,490.41M
2,978.48M
-1,774.33M
6,991.32M
4,418.14M
Income before tax
2,624.15M
3,151.73M
-1,413.07M
6,020.02M
4,823.65M
Net income
1,890.75M
2,335.21M
-976.92M
4,448.35M
3,606.40M
EBITDA
2,685.28M
3,491.82M
-1,261.79M
7,562.34M
5,051.15M
Diluted EPS
14.56
17.79
-7.80
34.26
27.77
Dividends Per Share
0
0
0
0
0
Total Assets
13,628.45M
16,512.83M
17,817.34M
26,266.72M
26,619.16M
Total liabilities
1,447.65M
1,804.11M
839.05M
5,049.72M
1,620.57M
Total equity
12,180.80M
14,708.71M
16,978.28M
21,217.00M
24,998.59M
Operating cash flow
1,530.77M
1,022.71M
241.98M
1,732.73M
6,654.70M
Jun 2017 Jun 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
44.87M
58.24M
19.03M
109.36M
85.24M
Gross Profit
32.35M
42.12M
6.06M
88.60M
63.14M
Operating income
22.82M
26.99M
-16.27M
65.48M
40.21M
Income before tax
24.05M
28.56M
-12.96M
56.38M
43.90M
Net income
17.33M
21.16M
-8.96M
41.66M
32.82M
EBITDA
24.61M
31.64M
-11.57M
70.82M
45.97M
Diluted EPS
0.13
0.16
-0.07
0.32
0.25
Dividends Per Share
0
0
0
0
0
Total Assets
121.29M
149.07M
163.95M
254.41M
231.15M
Total liabilities
12.88M
16.28M
7.72M
48.91M
14.07M
Total equity
108.40M
132.79M
156.22M
205.50M
217.08M
Operating cash flow
14.03M
9.26M
2.21M
16.22M
60.56M
Valuation Measures
Dec 2021
PER 90.96 ROA 13.63% ROE 15.60% Operating margin 47.17% Profit margin 38.50%
Key executives
President, CEO & Representative Director:
Patrick Crawford Reid
Chief Operating Officer, Director & Vice President:
Keiichi Masuya
Chief Financial Officer, Director & Vice President:
Kiyofumi Kaneshiro
Director-Public Relations & Investor Relations:
Yuko Okimoto Shareholders
KUBOTA KIICHI (10.4%)
SUGA HIROAKI (9.3%)
Taiyo Pacific Partners LP (6.1%)
JOHCM (Singapore) Pte Ltd. (4.4%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.6%)
REID PATRICK C (3.4%)
MURAKAMI HIROSHI /PEPTIDREAM INC/ (3.3%)
Invesco Advisers, Inc. (2.3%)
Baillie Gifford & Co. (2.3%)
Nomura Asset Management Co., Ltd. (2.2%)
Related Companies
PeptiAID, Inc.
Fujifilm Toyama Chemical /Radiopharmaceutical Bus/
Peptidream Board Incentive Plan
Peptidream Employee Incentive Plan
PharmaDesign, Inc. (Japan) /Pharma Research Bus/
PharmaDesign, Inc. (Japan)
Competitors
Aileron Therapeutics, Inc.
Apellis Pharmaceuticals, Inc.
Bicycle Therapeutics Plc Sponsored ADR
Protagonist Therapeutics, Inc.
UCB S.A.
Avidity Biosciences Inc
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 16 Aug, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close